Lumefantrine Impurities
General Information
Lumefantrine Impurities and Lumefantrine
Daicel Pharma offers the best-quality Lumefantrine impurities, such as N-Nitroso Lumefantrine Impurity. They are vital for evaluating Lumefantrine quality, stability, and biological safety. Furthermore, Daicel Pharma specializes in the custom synthesis of Lumefantrine impurities and ensures their worldwide delivery.
Lumefantrine [CAS: 82186-77-4] or Benflumetol, is an antimalarial drug. It is a synthetic amino alcohol fluorene derivative. It treats malaria caused by Plasmodium falciparum species. It blocks nucleic acid and protein synthesis by forming a hemin complex.
Lumefantrine: Use and Commercial Availability
Lumefantrine treats uncomplicated malaria tropica. It treats patients with chloroquine-resistant malaria. It combines with artemether in treating multi-drug-resistant malaria, especially Plasmodium species. It is a part of the artemisinin-based combination therapy. It is available as an oral formulation under the brand Coartem.
Lumefantrine Structure and Mechanism of Action
The chemical name of Lumefantrine is (9Z)-2,7-Dichloro-9-[(4-chlorophenyl)methylene]-α-[(dibutylamino)methyl]-9H-fluorene-4-methanol. The chemical formula for Lumefantrine is C30H32cl3NO, and its molecular weight is approximately 528.94 g/mol.
The precise mechanism of action of Lumefantrine is unknown.
Lumefantrine Impurities and Synthesis
During Lumefantrine synthesis, impurities form that may affect drug safety and efficacy. They form during the manufacturing, purification, or storage of Lumefantrine. Therefore, Lumefantrine impurities must be controlled and monitored throughout the drug’s development.
Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Lumefantrine impurities, which includes N-Nitroso Lumefantrine Impurity. We provide the CoA from a cGMP-compliant analytical facility. It gives complete characterization data1 such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity2. We provide additional analytical data on request. Daicel Pharma can prepare any unidentified Lumefantrine impurity or degradation product. In addition, Daicel Pharma offers highly purified, stable isotope-labeled standards of Lumefantrine. Clients receive a complete characterization report upon delivery.
References
FAQ's
References
- Blessborn, D.; Roemsing, S.; Annerberg, A.; Sundquist, D.; Bjoerkman, A.; Lindegardh, N.; Bergqvist, Y., Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper, Journal of Pharmaceutical and Biomedical Analysis, Volume: 45, Issue: 2, Pages: 282-287, 2007 DOI: (1016/j.jpba.2007.07.015)
- Zeng, Mei-Yi; Lu, Zhi-Liang; Yang, Song-Cheng; Zhang, Min; Liao, Jie; Liu, Shu-Ling; Teng, Xi-He, Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 681, Issue: 2, Pages: 299-306, 1996 DOI: (1016/0378-4347(95)00542-0)
Frequently Asked Questions
Which analytical method identifies and separates Lumefantrine impurities?
The HPLC-DAD method helps to identify and separate Lumefantrine impurities.
How do the Lumefantrine impurities and degradation products form?
Unreacted starting materials, by-products, reagents, and catalysts during synthesis and poor storage conditions may form Lumefantrine impurities and degradation products.
Why should Lumefantrine be removed from the drug?
Lumefantrine impurities' presence in the drug can affect its safety, quality, and efficacy.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.